Patent applications published 15 June 2011
Selected patent applications from the weekly European Patents Bulletin
- Solid core microcapsular compsns and uses
Botanocap 2330890*
- Methods of treatment using ammonia-scavenging drugs
Ucyclyd Pharma 2330892*
- Deep lung pulmonary delivery of treprostinil
Aradigm Crop 2330893*
- Compsns including 6-amino-hexanoic acid derivatives as HDAC inhibitors
Repligen 2330894*
- Short acting benzothiazepine calcium channel blockers and uses thereof
Milestone Pharmaceuticals 2330895*
- Antinecrotic activity of alpha 1-antitrypsin
Ben Gurion University of the Negev Research & Development Authority 2330896*
- NGAL-binding sideriphores and use thereof to treat iron deficiency and iron overload
The Trustees of Columbia University in the City of New York 2330897*
- Methods of treating neuropathic pain
Richter Gedeon 2330899*
- Treatment for leukaemia and idiopathic aplastic anaemia
Sphingomonas Research Partners 2330901*
- Chemical compounds
GlaxoSmithKline; Shionogi&Co 2330902*
- Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist
Endogenx 2330903*
- 4-alkyl-substituted diamonopyrimidines
Bayer CropScience 2330904*
- Modified release emulsions for application to skin or vaginal mucosa
Polichem 2331065*
- Mucomimetic compsns and uses therefore
Chemisches Institut Schaefer 2331066*
- Progestin-containing drug delivery system
Bayer Schering Pharma 2331067*
- Benzimidazole anthelmintic compsns
Wyeth 2331068*
- Heterogeneous polymeric micelles for intracellular delivery
University of Washington; Phaserx 2331069*
- Method of solubilising biologically active compounds
Phares Pharmaceutical Research 2331070*
- Useful multimodular assembly useful for intracellular delivery
Institut National de la Sante et de la Recherche Medicale 2331071*
- Methods and compsns for oral administration of proteins
Oramed 2331972*
- New controlled release active agent carrier
Omya Development 2331073*
- Granulates, process for preparing them, and pharmaceutical products containing them
Mylan Laboratories 2331074*
- Controlled release peptide formulations
Genzyme 2331075*
- Chewable sustained release formulations
Farnam Companies 2331076*
- Stable formulation comprising therapeutic polypeptides for oral adminstration
Ironwood Pharmaceuticals 2331077*
- Lyophilised formulations of engineered anti-IL-23P19 antibodies
Schering 2331078*
- Pharmaceutical formulation
Bolgic, Mahmut 2331079*
- Pharmaceutical compsns configured to deter dosage form splitting
Abuse Deterrent Pharmaceutical 2331080*
- Organic acid free effervescent formulation
Tower Laboratories 2331081*
- Solvent extraction microencapsulation with tunable extraction rates
Surmodics Pharmaceuticals 2331082*
- Prolonged release multiparticulate pharmaceutical compsn comprising paliperidone
KRKA 2331083*
- Pharmaceutical compsn comprising amorphous esomeprazole, dosage forms and process thereof
Jubilant Life Sciences 2331084*
- Devices and systems for local delivery of inotropic agents to the epicardium
Massachusetts Institute of Technology 2331085*
- Novel formulation
Crawford Healthcare Holdings 2331086*
- Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol paracetamol
Grünenthal 2331087*
- Compsns and methods for treating psychiatric disorders
Gosforth Centre (Holdings) 2331088*
- Use of sesquiterpene derivatives
Kwang Dong Pharm 2331089*
- Stable liquid antibody formulation
Pfizer 2331090*
- Pharmaceutical combination of 1-(2-tetrahydrofuryl)-5-fluorouracil and caffeic acid phenethyl ester for oral treating of tumours
Grindeks; Chemco Ventures 2331091*
- Methods and compsns for administration of 3-halopyruvate and related compounds for the treatment of cancer
The Johns Hopkins University 2331092*
- Compounds, compsns and methods for reducing toxicity and treating or preventing diseases
The Trustees of Columbia University in the City of New York; Sloan Kettering Institute for Cancer Research 2331093*
- Novel anti-arrhythmia agent
The UAB Research Foundation 2331094*
- Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compsn, and methods of use thereof
CHDI 2331095*
- Dabigatran in tumour therapy
Boehringer Ingelheim International 2331096*
- Methods for treating CNS disorders
Richter Gedeon 2331097*
- Methods for the administration of iloperidone
Vanda Pharmaceuticals 2331098*